Insight Molecular Diagnostics Inc. IMDX
1.97 USD +0.31 (+18.67%)
Regular-session close
1.94 -0.03 -1.52%
After hours · Nov 20, 7:53 PM ET
1.62 Day range 2.01
1.59 52-week range 7.50
- YTD
- -73.73%
- 1 year
- -67.55%
5D -0.15 (-7.08%)
- Market cap
- 80.88M
- EPS (ttm)
- -1.27
- YTD return
- -73.73%
- 1-year return
- -67.55%
- Volume
- 1.20M
- Avg volume
- 243.75K
- Open
- 1.76
- Previous close
- 1.66
- Day's range
- 1.62 – 2.01
- 52-week range
- 1.59 – 7.50
Fundamental scorecard
5 of 25 checks passed on IMDX’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
IMDX Revenue — quarterly 559.00K
IMDX Net income — quarterly -3.58M
IMDX EPS — quarterly -0.10
News
Lake Street Maintains Buy on Insight Molecular, Lowers Price Target to $9
Insight Molecular Diagnostics Enrolls First Several Patients In Its GALACTIC Study Evaluating GraftAssure Molecular Test For Monitoring Rejection In Kidney Transplant Recipients
iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study Stephens & Co. Reiterates Equal-Weight on Insight Molecular, Maintains $4 Price Target
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript
What Oncocyte (IMDX) Said on Its Q3 Earnings Call
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
Your note
Sign in to keep a note on IMDX — it syncs with the Stock Master app.
